ThePrint on MSN2d
Cipla set to bring Afrezza, 1st inhalable insulin since Exubera, to Indian markets by 2025Afrezza, world’s only rapid-acting, inhaled insulin for type 1 & type 2 diabetes patients & manufactured by MannKind, ...
Stocktwits on MSN4d
MannKind Stock Gains After India Approves Inhaled Insulin: Retail Excitement BuildsShares of MannKind Corporation climbed more than 2% in premarket trading Wednesday, on track to extend gains from the ...
India has the 2nd highest burden of diabetes worldwideCDSCO decision follows existing approvals in the U.S.A. and BrazilMannKind expects to ship ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback